Reversal of TGF-β-induced epithelial-mesenchymal transition in hepatocellular carcinoma by sorafenib, a VEGFR-2 and Raf kinase inhibitor

• Hoofdauteurs: Siddharth J. Modi (Auteur), Anshuly Tiwari (Auteur), Vithal M. Kulkarni (Auteur)
• Formaat: Boek
• Gepubliceerd in: Elsevier, 2021-01-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

The epithelial-mesenchymal transition (EMT) is considered an essential process for cancer development and metastasis. Sorafenib, a RAF kinase and VEGFR-2 inhibitor, exhibits efficacy against advanced hepatocellular carcinoma (HCC), renal carcinoma, and thyroid cancer. It is well established that tra...